With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.5631-96-9,2-(2-Chloroethoxy)tetrahydro-2H-pyran,as a common compound, the synthetic route is as follows.
5631-96-9, 2-(2-Chloroethoxy)tetrahydro-2H-pyran (148 g, 0.9 mol) was added to a mixture of aqueous sodium hydroxide solution (50 %, 888 ml), tetra-n-butylammonium hydrogen sulfate (305 g, 0.90 mol) and benzene (1480 ml) and the mixture was stirred at 600 C. After approx. 6 h, there was no more conversion (there was always starting material left). Diethyl ether (2 I) and water (2 I) were added and the phases were separated. The organic layer was washed with water (1 I) and the combined aqueous phases were extracted once with diethyl ether (1 I). The combined ethereal layers were dried over magnesium sulfate, and distilled with a vigreux column, first at normal pressure (most of the solvent – diethyl ether and benzene – was distilled off), then under reduced pressure, affording three fractions containing 2-(vinyloxy)tetrahydro-2/-/-pyran: F1 : 16 g (60mbar, 65 0C, 65 % product (+ benzene, 1H NMR) F2: 56 g (60mbar, 95 0C, 90 % product (+ tributylamine, 1H NMR) F3: 19 g (60-40mbar, 95 0C, 80 % product (+ tributylamine, 1H NMR)
As the paragraph descriping shows that 5631-96-9 is playing an increasingly important role.
Reference£º
Patent; NYCOMED GMBH; WO2008/95912; (2008); A2;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics